Ceryvyn Therapeutics Ltd
UKJ2
Company Profile
Business description
Ceryvyn Therapeutics Ltd is an Australian biotechnology company developing a biologic therapy for the rare disease LAM (lymphangioleiomyomatosis). It is engaged in the investigation of CYV-101 as a potential treatment for Lymphangioleiomyomatosis (LAM). It operates in one segment, being the biotechnology and healthcare industry in Australia.
Contact
c/-Bio101 Financial Advisory Pty Ltd
Suite 1.01, 117 Camberwell Road
Hawthorn East
MelbourneVIC3123
AUST: +61 398260399
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
10
Stocks News & Analysis
stocks
Long term outlook intact for wide moat income share
Acquisition gains balance traffic headwinds.
stocks
ASX rare earths play looks to expand production
The largest rare-earth producer outside of China acquires competitor to increase production.
stocks
Anthropic’s leaked financials reflect fast growth, but not a $2 trillion valuation
Draft IPO filing shows a company growing faster than its annual results can capture.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,903.50 | 44.30 | 0.50% |
| CAC 40 | 7,865.07 | 30.97 | 0.40% |
| DAX 40 | 25,449.19 | 194.98 | 0.77% |
| Dow JONES (US) | 51,521.28 | 253.38 | 0.49% |
| FTSE 100 | 10,541.69 | 43.75 | 0.42% |
| HKSE | 24,280.56 | 240.22 | 1.00% |
| NASDAQ | 27,599.79 | 122.48 | 0.45% |
| Nikkei 225 | 70,683.98 | 737.12 | 1.05% |
| NZX 50 Index | 13,713.30 | 13.18 | 0.10% |
| S&P 500 | 7,818.93 | 44.98 | 0.58% |
| S&P/ASX 200 | 8,735.70 | 49.30 | 0.57% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |